Navigation Links
Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
Date:10/24/2007

d statin therapy," said Paul F. Truex, President and Chief Executive Officer of Anthera Pharmaceuticals. "Importantly, based upon these results, we will propose utilizing metabolic endpoints for our Phase III program, which may warrant smaller trials based on improvements in cholesterol and markers of inflammation."

"This trial revealed that A-002 treatment resulted in significant positive changes on lipoproteins and inflammation, major etiological factors that lead to atherosclerosis among cardiovascular patients treated with statins," said Dr. Robert Rosenson, Director of Lipoprotein Disorders and Clinical Atherosclerosis Research at the University of Michigan and lead investigator for the PLASMA trial. "Of particular interest was the marked reduction in small LDL particles that are associated with the development of atherosclerosis."

The company expects to meet with the FDA in December to discuss the results of the trial and plans for Phase III. At present, Anthera anticipates the A-002 Phase III program will target patients with coronary heart disease with associated hyperlipidemia and inflammation who are currently not achieving adequate cholesterol control with diet, exercise, and existing statin therapies such as Lipitor(R). PLASMA-2, the once-daily Phase II trial of A-002, has completed enrollment and data is expected in the first quarter of 2008.

Further information about Anthera's clinical trials can be found at http://www.PLASMAtrial.com or http://www.anthera.com.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a privately-held company committed to developing and commercializing clinical pharmaceutical products that address unmet medical needs of patients with life-threatening, chronic and acute inflammatory diseases. The Company has acquired from Eli Lilly and Company and Shionogi & Co. Ltd. worldwide rights (ex
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Israel , September 2, 2014 ... (TASE, NASDAQ: EMITF ) announced today following ... Medical Technologies Ltd. ("Elbit Medical") (TASE: EMTC-M), a subsidiary ... on a fully diluted basis, announced that on September ... holds approximately 30.8% of the voting power ("Gamida Cell") ...
(Date:9/2/2014)... Bluegrass Vascular Technologies (BVT), ... lifesaving devices and methods for vascular access procedures, ... Niederauer , a seasoned senior medical device executive, ... of Series A financing, BVT is focused on ... Catheter System, a proprietary system that allows physicians ...
(Date:9/2/2014)... SOUTH SAN FRANCISCO, Calif. , Sept. 2, 2014 /PRNewswire/ ... announced that Bonnie H. Anderson , president and chief ... at the Morgan Stanley Global Healthcare Unplugged Conference 2014 on ... New York . The live audio ... website at http://investor.veracyte.com . Please connect to the website ...
Breaking Medicine Technology:Elbit Imaging Announces Gamida Cell Closed Option and Investment Agreements with a Major Pharmaceutical Company 2Elbit Imaging Announces Gamida Cell Closed Option and Investment Agreements with a Major Pharmaceutical Company 3Bluegrass Vascular Technologies Names Dr. Gabriele Niederauer President And CEO 2Veracyte to Present at the Morgan Stanley Global Healthcare Unplugged Conference 2014 2
... Stereotaxis, Inc. (Nasdaq: STXS ) announced today ... million credit facility, which includes a $30 million revolving facility ... term loan that matures on December 31, 2013.  The new ... Company,s previous facility that was scheduled to mature in March ...
... TARRYTOWN, N.Y. and BERLIN, Dec. 20, 2010 Regeneron ... HealthCare today announced positive top-line results for VEGF Trap-Eye ... led by Regeneron, the first of two Phase 3 ... retinal vein occlusion (CRVO).  In this trial, 56.1 percent ...
Cached Medicine Technology:Stereotaxis Completes $40 Million Credit Facility 2Stereotaxis Completes $40 Million Credit Facility 3Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME) 2Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME) 3Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME) 4Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME) 5Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME) 6Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME) 7Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME) 8Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME) 9
(Date:9/2/2014)... public support for marijuana legalization in the U.S. has ... than other substances, such as alcohol. In January, President ... marijuana is more dangerous than alcohol. Despite the recent ... as compared to alcohol use are not well understood. ... Outcomes Associated with Drug Use among US High School ...
(Date:9/2/2014)... At the 50th Annual Mr. Olympia Fitness ... exhibitor at the Las Vegas Convention Center South Hall, ... Booth #374 Sept 19th and 20th 10am-5PM. , ... exercise, diet and supplementation. They pride themselves on creating ... for all Prosupps customers to reach their personal health ...
(Date:9/2/2014)... 2014 Smile Squared, a well-known Buy ... to include a US-made toothbrush. For every toothbrush purchased, ... , “Smile Squared was created by my wife and ... said Eric Cope, President of Smile Squared. “There, we ... problems. But many of the same children didn't own ...
(Date:9/2/2014)... Spain Tuesday 2 September 2014: Digoxin may increase ... (AF) by approximately 20%, according to results from the ... Dr Manesh Patel, director of interventional cardiology and catheterisation ... Carolina, US. The findings suggest that caution may be ... further studies are needed to confirm the observations. , ...
(Date:9/2/2014)... Spain Tuesday 2 September 2014: The fact that ... has been confirmed by data from the ROPAC registry ... Congress Hot Line session by Professor Jolien W. Roos-Hesselink, ... committee. The registry found that 1.4% of pregnant women ... their baby during pregnancy. , The Registry Of Pregnancy ...
Breaking Medicine News(10 mins):Health News:NYU study compares consequences of teen alcohol and marijuana use 2Health News:NYU study compares consequences of teen alcohol and marijuana use 3Health News:Prosupps, One of the Fastest Growing Supplement Companies, Celebrates a Success Milestone with Exhibiting at the 50th Annual 2014 Mr. Olympia’s Fitness & Performance Expo 2Health News:Smile Squared's Colorful Buy One, Give One Toothbrush Now Available in Schnucks Stores 2Health News:ROCKET AF trial suggests that digoxin increases risk of death in AF patients 2Health News:Mechanical heart valves increase pregnancy risk 2Health News:Mechanical heart valves increase pregnancy risk 3
... 2009 The first results of the first European survey ... at the 6th congress of the European Federation of Chapters ... , Previous surveys have looked at the overall management of ... study to look in detail at Breakthrough Cancer Pain (BTCP) ...
... ... relationship to offer comprehensive staffing, scheduling, and credentialing software to nurse staffing ... no additional charge. , ... Nashville, TN (Vocus) September 11, 2009 -- BlueSky Synergy, LLC (BlueSky) and People ...
... ... Yum-Yum D3 Gummies, Yum-Yum GOS Syrup (prebiotic fiber syrup), and Yum-Yum Zymes at the ... and Exhibition Center in Boston, MA, September 24-26, 2009. , ... Los Angeles, CA (PRWEB) September 11, 2009 ...
... ... dental group practice in central North Carolina, today announced the addition of Dr. Brian Cahill ... ... pleased to announce that Dr. Brian Cahill has joined their cosmetic and family dental practice. ...
... , , NEW YORK, Sept. 10 ... The Mount Sinai Medical Center describe the Community Diabetes and ... program which was designed specifically for people from the vulnerable Latino ... Twenty-five patients from The Mount Sinai Medical Center were randomly selected ...
... speed immunity, experts say , THURSDAY, Sept. 10 (HealthDay ... vaccine conducted in Australia and Britain show that a ... virus within about 10 days. , That,s a potentially ... would be needed to provide full immunity to the ...
Cached Medicine News:Health News:First results from major European patient survey show devastating impact of living with breakthrough cancer pain 2Health News:BlueSky Synergy, a Division of Amistaff Healthcare Technology, and People 2.0 Global Partner to Provide Complimentary Staffing Software to Participating Companies 2Health News:BlueSky Synergy, a Division of Amistaff Healthcare Technology, and People 2.0 Global Partner to Provide Complimentary Staffing Software to Participating Companies 3Health News:Jarrow Formulas, Inc. to Unveil Children's Natural Health Products at Upcoming Natural Products Expo East Show in Boston 2Health News:Jarrow Formulas, Inc. to Unveil Children's Natural Health Products at Upcoming Natural Products Expo East Show in Boston 3Health News:Dr. Brian Cahill Joins Research Triangle Dental 2Health News:Dr. Eliscer Guzman, with The Mount Sinai Medical Center, Join Forces to Celebrate the Community Diabetes and Cardiovascular Care Program's Graduation Ceremony on September 16th 2Health News:One Dose of Swine Flu Vaccine Offers Protection: Studies 2Health News:One Dose of Swine Flu Vaccine Offers Protection: Studies 3
... The SureStep™ Drug Screen Tests are ... assay for MDMA (Ecstasy). Designed using Microgenics ... is the only point of care immunoassay ... affinity for both MDA and MDEA but ...
... The SureStep™ Drug Screen Tests are ... assay for MDMA (Ecstasy). Designed using Microgenics ... is the only point of care immunoassay ... affinity for both MDA and MDEA but ...
AccuSign® DOA Series Opiates Test...
... The SureStep™ Drug Screen Tests are available ... for MDMA (Ecstasy). Designed using Microgenics Antibody ... the only point of care immunoassay targeted ... for both MDA and MDEA but no ...
Medicine Products: